Zollinger‑Ellison Syndrome (Type II) – A Patient‑Focused Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease and diarrhea. ZES is divided into two clinical types:

• Type I – associated with chronic atrophic gastritis (autoimmune).
• Type II – occurs in patients with multiple endocrine neoplasia type 1 (MEN‑1) syndrome.

This guide focuses on **type II ZES**, the form linked to MEN‑1.

Who is affected?

• Both men and women; slight male predominance (≈55 %).
• Usually diagnosed in the 3rd–5th decade of life, but can appear earlier in MEN‑1 families.
• Patients with a known MEN‑1 gene mutation have a 20–30 % lifetime risk of developing gastrinomas.

Prevalence

Zollinger‑Ellison syndrome is extremely rare, affecting about 1 in 1–3 million individuals worldwide. Type II accounts for roughly 20–30 % of all ZES cases, reflecting the prevalence of MEN‑1 in the general population (≈1 in 30,000 individuals) ^[1].

Symptoms

Symptoms stem from hyperacidity and tumor effects. Not every patient experiences all of them; the pattern can vary.

Gastro‑intestinal (GI) symptoms

• Abdominal pain – usually epigastric, worsening 1–3 h after meals.
• Refractory or recurrent peptic ulcers – may be multiple, large, or located beyond the duodenum (e.g., jejunum).
• Diarrhea – watery, often 3–8 BMs/day; can be caused by acid inactivation of pancreatic enzymes.
• Steatorrhea – fatty stools due to malabsorption.
• Nausea / vomiting – especially with ulcer complications.
• Gastro‑esophageal reflux disease (GERD) – heartburn, regurgitation.

Systemic symptoms

• Weight loss – from malabsorption and chronic diarrhea.
• Fatigue / anemia – chronic GI bleeding can cause iron‑deficiency anemia.
• Osteopenia / osteoporosis – long‑standing acid‑induced malabsorption of calcium and vitamin D.

MEN‑1 related symptoms (may coexist)

• Hyperparathyroidism (high calcium, kidney stones).
• Pituitary adenomas (headaches, visual changes, hormonal imbalances).

Causes and Risk Factors

Underlying cause

Type II ZES is caused by **gastrin‑producing neuroendocrine tumors (gastrinomas)** that arise in the context of **multiple endocrine neoplasia type 1 (MEN‑1)**. MEN‑1 is an autosomal‑dominant genetic disorder caused by mutations in the MEN1 tumor suppressor gene, which encodes the protein menin.

Risk factors

• Family history of MEN‑1 – 50 % of MEN‑1 cases are inherited.
• Known MEN1 gene mutation – carriers have a lifelong risk of neuroendocrine tumors, including gastrinomas.
• Age – risk rises after puberty; median age of gastrinoma diagnosis in MEN‑1 is ~35 years.
• Sex – slight male predominance, though risk is similar in females.
• Environmental factors – none clearly linked; the condition is largely genetic.

Diagnosis

Because the symptoms mimic common GI disorders, a high index of suspicion is necessary, especially in patients with MEN‑1 or refractory ulcers.

Initial assessment

• Detailed medical and family history (MEN‑1, peptic ulcer disease).
• Physical exam – look for signs of anemia, abdominal tenderness, or MEN‑1 manifestations.

Laboratory tests

• Fasting serum gastrin – markedly elevated (> 1,000 pg/mL) in >90 % of ZES patients. Levels >10× upper limit with gastric pH < 2 are diagnostic ^[2].
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase) confirms gastrinoma.
• Basic metabolic panel, calcium, parathyroid hormone (PTH) – assess MEN‑1 endocrine involvement.
• Complete blood count – detect anemia.

Imaging studies

• Endoscopic ultrasound (EUS) – highly sensitive for small duodenal or pancreatic gastrinomas.
• Multiphasic contrast CT or MRI – locate larger tumors, assess metastasis.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – gold standard for neuroendocrine tumor localization and staging.
• Selective arterial secretin stimulation test – regionalizes gastrin source when imaging is equivocal.

Pathology

If surgical resection is performed, histology confirms a well‑differentiated neuroendocrine tumor with immunohistochemical positivity for gastrin.

Treatment Options

Management combines **acid suppression**, **tumor control**, and **addressing MEN‑1 manifestations**.

Acid‑blocking therapy (first line)

• High‑dose proton pump inhibitors (PPIs) – e.g., omeprazole 60–80 mg/day or esomeprazole 40 mg twice daily. Aim for symptom control and ulcer healing.
• Histamine‑2 receptor antagonists (H2RAs) – less effective alone; may be added for breakthrough symptoms.
• PPIs are usually required long‑term; dose may be tapered after tumor control.

Surgical management

• Localized gastrinoma – enucleation or segmental pancreaticoduodenectomy.
• Multiple or metastatic disease – debulking surgery plus adjunctive therapies.
• In MEN‑1 patients, surgery is often deferred until tumors are >2 cm or symptomatic, because many gastrinomas are small and multifocal.

Medical therapies for tumor control

• Somatostatin analogues (octreotide LAR, lanreotide) – inhibit gastrin release and may reduce tumor size.
• Targeted therapy – everolimus or sunitinib for progressive, unresectable neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive disease.
• Chemotherapy – reserved for high‑grade, rapidly progressive disease.

Management of MEN‑1 components

• Hyperparathyroidism – parathyroidectomy.
• Pituitary adenoma – surgery, dopamine agonists, or radiotherapy as indicated.

Lifestyle & supportive measures

• Low‑fat, low‑fiber diet while diarrhea is active (easier digestion).
• Avoid NSAIDs, aspirin, and alcohol – they aggravate ulceration.
• Calcium and vitamin D supplementation if bone loss is present.
• Regular dental care – acid can erode enamel.

Living with Zollinger‑Ellison Syndrome (type II)

Medication adherence

• Take PPIs exactly as prescribed; never stop abruptly without medical guidance.
• Keep a medication list and share it with every new health‑care provider.

Monitoring

• Serum gastrin every 6–12 months (or sooner if symptoms change).
• Annual endoscopy to assess ulcer healing.
• Imaging (CT/MRI) every 1–2 years for tumor surveillance, more frequently if lesions are known.

Nutrition

• Small, frequent meals; avoid large boluses that stimulate acid release.
• If steatorrhea persists, consider pancreatic enzyme replacement (creon).
• Stay hydrated; oral rehydration solutions help replace electrolytes lost with diarrhea.

Psychosocial care

• Connect with MEN‑1 support groups (e.g., International MEN1 Society).
• Consider counseling for anxiety or chronic illness fatigue.
• Employ strategies for work or school accommodations—document the condition with a physician’s note.

Family planning

• MEN‑1 is hereditary; genetic counseling is recommended for individuals planning children.
• Pregnancy: PPIs are generally safe, but surveillance for ulcer complications should be intensified.

Prevention

Because type II ZES is genetically driven, primary prevention is limited. However, the following steps can reduce disease impact:

• Genetic testing for at‑risk relatives; early identification allows surveillance before symptoms develop.
• Regular endocrine screening in MEN‑1 carriers (calcium, PTH, prolactin, IGF‑1) to treat associated tumors promptly.
• Avoidance of ulcer‑aggravating agents (NSAIDs, heavy alcohol) can lessen the severity of acid‑related damage.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

• Refractory or perforated peptic ulcers – can cause peritonitis, hemorrhage, or need for emergency surgery.
• Gastrointestinal bleeding – chronic anemia, transfusion requirement.
• Severe malabsorption – weight loss, deficiencies (iron, B12, fat‑soluble vitamins), osteoporosis.
• Electrolyte disturbances – hypokalemia, metabolic alkalosis from chronic diarrhea.
• Metastatic neuroendocrine tumor – liver, lymph node, or bone spread worsens prognosis.
• MEN‑1 related cancers – pancreatic neuroendocrine carcinoma, pituitary adenoma, parathyroid carcinoma.
• Reduced quality of life – chronic pain, fatigue, and anxiety.

When to Seek Emergency Care

References

1. Thakker RV, et al. "Multiple endocrine neoplasia type 1 (MEN1)." GeneReviews. 2022. link.
2. Mayo Clinic. "Zollinger-Ellison syndrome - Diagnosis and treatment." 2023. link.
3. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Zollinger-Ellison Syndrome." 2022. link.
4. American College of Gastroenterology. "Guidelines for the Management of Peptic Ulcer Disease." 2022. link.
5. World Health Organization. "Neuroendocrine Tumors of the Digestive System." WHO Classification, 5th edition, 2023.
6. Colenso CK, et al. "Management of Gastrinomas in MEN1." Cleveland Clinic Journal of Medicine. 2021;88(5):315‑324.